Passage Bio, Inc.
PASG
$4.94
$0.091.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.06% | -21.33% | 4.46% | -40.04% | -30.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.14% | -35.75% | -27.54% | -45.59% | -39.00% |
| Operating Income | 1.14% | 35.75% | 27.54% | 45.59% | 39.00% |
| Income Before Tax | 16.66% | 50.93% | -2.03% | 59.93% | 41.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.66% | 50.93% | -2.03% | 59.93% | 41.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.66% | 50.93% | -2.03% | 59.93% | 41.31% |
| EBIT | 1.14% | 35.75% | 27.54% | 45.59% | 39.00% |
| EBITDA | -0.26% | 35.75% | 25.00% | 44.06% | 37.03% |
| EPS Basic | 17.70% | 51.57% | -1.11% | 60.34% | 41.80% |
| Normalized Basic EPS | -2.76% | 36.68% | 26.20% | 47.26% | 40.16% |
| EPS Diluted | 17.70% | 51.57% | -1.11% | 60.34% | 41.80% |
| Normalized Diluted EPS | -2.76% | 36.68% | 26.20% | 47.26% | 40.16% |
| Average Basic Shares Outstanding | 1.26% | 1.33% | 0.90% | 1.02% | 0.84% |
| Average Diluted Shares Outstanding | 1.26% | 1.33% | 0.90% | 1.02% | 0.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |